NCT06297642View on ClinicalTrials.gov

TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors.

PHASE1TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

May 24, 2024

Primary Completion Date

July 31, 2024

Study Completion Date

July 31, 2024

Conditions
Advanced Malignant Neoplasm
Interventions
DRUG

TQB2928 injection

Anti-CD47 monoclonal antibody

DRUG

Penpulimab

Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1)

Trial Locations (5)

100021

Cancer Hospital Chinese Academy of Medical Science, Beijing

230012

The Second People's Hospital of Hefei, Hefei

237008

Lu'an People's Hospital of Anhui Province, Lu'an

510000

Sun Yat-sen University Cancer Center, Guangzhou

730000

Gansu Provincial Cancer Hospital, Lanzhou

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY